First North Denmark: Brain+ A/S - increase and admittance to trading of TO 4 (warrants)

New shares in Brain+ A/S will be admitted to trading on Nasdaq First North
Growth Market Denmark as per 11 July 2024. New shares are issued due to
completion of a rights issue of units consisting of 11 new shares and 9
warrants of series TO 4.Also, as of 11 July 2024, warrants of series TO 4 will
be admitted to trading, cf. below. 



Name:              Brain+      
---------------------------------------------------
ISIN:              DK0061670205   
---------------------------------------------------
Short name:           BRAINP      
---------------------------------------------------
Number of shares before change: 91,449,279 shares 
---------------------------------------------------
Change (rights issue):      74,453,390 shares 
---------------------------------------------------
Change (directed issue):     5,598,472 shares 
---------------------------------------------------
Number of shares after change:  171,501,141 shares
---------------------------------------------------
Face value:           DKK 0.08     
---------------------------------------------------
Orderbook ID:          235014      
---------------------------------------------------



TO 4 warrants

Name:             Brain+ TO 4                   
--------------------------------------------------------------------------------
ISIN:             DK0062955761                   
--------------------------------------------------------------------------------
Short name:          BRAINP TO4                    
--------------------------------------------------------------------------------
Number of warrants:      65,496,978 warrants               
--------------------------------------------------------------------------------
Exercise periode, both days  16 September to 27 September 2024        
 incl.:                                     
--------------------------------------------------------------------------------
Last day of trading:      25 September 2024                
--------------------------------------------------------------------------------
Terms:             Please see the company announcement published on 
                7 May 2024                   
--------------------------------------------------------------------------------
Market segment:        First North Denmark / 100            
--------------------------------------------------------------------------------
Tick Size table:        MiFID II tick size table             
--------------------------------------------------------------------------------
MIC code:           DSME                       
--------------------------------------------------------------------------------
Orderbook ID:         341851                      
--------------------------------------------------------------------------------



For further information, please call Certified Adviser: Keswick Global AG

Gewinner im Megamarkt

Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!

Hier klicken

Zeit	Aktuelle Nachrichten
31.12.24	BRAIN A/S: Brain+ announces change of Certified Advisor
10.12.24	BRAIN A/S: Brain+ invites to investor webinar to update on UK commercial pipeline and status
05.12.24	BRAIN A/S: Brain+ secures its first multi-year sales contract for Ayla - your CST Assistant with Syddjurs municipality
01.11.24	BRAIN A/S: Brain+ closes new Danish municipality sales contract on Ayla - your CST Assistant
21.10.24	BRAIN A/S: Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy

Zeit

Aktuelle Nachrichten

31.12.24

BRAIN A/S: Brain+ announces change of Certified Advisor

10.12.24

BRAIN A/S: Brain+ invites to investor webinar to update on UK commercial pipeline and status

05.12.24

BRAIN A/S: Brain+ secures its first multi-year sales contract for Ayla - your CST Assistant with Syddjurs municipality

01.11.24

BRAIN A/S: Brain+ closes new Danish municipality sales contract on Ayla - your CST Assistant

21.10.24

BRAIN A/S: Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy

	Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Xetra-Orderbuch


	Fonds	Kurs	%


	Devisen	Kurs	%


	Rohstoffe	Kurs	%


	Themen	Kurs	%



Erweiterte Suche

BRAIN+ A/S

First North Denmark: Brain+ A/S - increase and admittance to trading of TO 4 (warrants)